Innovus Pharmaceuticals 10-Q 14 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 08, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'INNOVUS PHARMACEUTICALS, INC.	'
Entity Central Index Key	'0001411879	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'INNV	'
Entity Common Stock, Shares Outstanding	'	18,143,398
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
ASSETS	'	'
Cash	$25,876	$18,445
Accounts receivable	75,165	0
Prepaid expenses	21,200	0
Total Current Assets	122,241	18,445
OTHER ASSETS	'	'
Intangible assets	4,149	0
CIRCUMserum License (see note 8)	250,000	0
TOTAL ASSETS	376,390	18,445
LIABILITIES AND STOCKHOLDERS' DEFICIT	'	'
Accounts payable	62,723	1,602
Accrued compensation	281,582	0
Deferred revenue	75,136	0
Promissory notes	20,000	50,000
Accrued interest (current portion)	2,744	'
Total Current Liabilities	442,185	51,602
NON-CURRENT LIABILITIES	'	'
Accrued interest payable (non-current portion)	34,957	16,596
Convertible debentures - related parties (non-current portion) (see Note 6)	539,276	162,668
Total Non-Current Liabilities	576,977	179,264
TOTAL LIABILITIES	1,016,418	230,866
STOCKHOLDERS' DEFICIT	'	'
Common stock; 150,000,000 shares authorized, at $0.001 par value, 18,089,264 and 16,197,782 shares issued and outstanding, respectively	18,089	16,198
Additional paid-in capital	4,979,226	2,220,202
Deficit accumulated during the development stage	-5,637,343	-2,448,821
Total Stockholders' Deficit	-640,028	-212,421
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$376,390	$18,445

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Sep. 30, 2013	Dec. 31, 2012
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	18,089,264	16,197,782
Common stock, shares outstanding	18,089,264	16,197,782

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		59 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
REVENUES	'	'	'	'	'
Product sales	$166	$0	$445	$0	$445
Total Revenues	166	0	445	0	445
OPERATING EXPENSES	'	'	'	'	'
Research and development	66,342	0	66,342	0	147,302
Investment banking fees	0	0	0	0	1,954,865
General and administrative	648,127	73,231	3,086,918	179,357	3,532,837
Total Operating Expenses	714,469	73,231	3,153,260	179,357	5,635,004
LOSS FROM OPERATIONS	-714,303	-73,231	-3,152,815	-179,357	-5,634,559
OTHER EXPENSE	'	'	'	'	'
Interest expense	-19,649	-4,288	-35,707	-12,743	-144,023
Total Other Expense	-19,649	-4,288	-35,707	-12,743	-144,023
NET LOSS	($733,952)	($77,519)	($3,188,522)	($192,100)	($5,778,582)
BASIC LOSS AND DILUTED LOSS PER SHARE (in dollars per share)	($0.04)	$0	($0.19)	($0.02)	'
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING (in shares)	17,848,558	16,333,670	17,030,496	10,549,045	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended		59 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'
Net loss	($3,188,522)	($192,100)	($5,778,582)
Adjustments to reconcile net loss to net cash used by operating activities:	'	'	'
Stock compensation	1,962,379	'	1,962,379
Common stock issued for services	354,421	0	363,809
Value of warrants granted to investment banker	0	0	1,904,865
Accretion of debt discount	8,017	0	8,017
Non-cash interest expense (including a discount on conversion of Apricus Bio convertible notes of $48,920)	0	0	91,897
Promissory note issued for services rendered	0	0	50,000
Research and development expense recognized upon purchase of SSAO inhibitor assets	0	0	20,000
Expenses paid on behalf of the Company by Apricus Bio	0	0	25,990
Changes in operating assets and liabilities	'	'	'
Accounts receivable	-75,165	0	-75,165
Prepaid expenses	-21,200	0	-21,200
Accounts payable	61,121	-512	62,723
Accrued compensation	281,582	0	281,582
Interest payable	22,563	12,743	39,158
Deferred revenue	75,136	0	75,136
Related-party payable	0	-12,500	0
Net Cash Used in Operating Activities	-519,668	-192,369	-989,391
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Purchase of intangible assets	-4,149	0	-4,149
Net Cash Used in Investing Activities	-4,149	0	-4,149
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'
Proceeds from issuance of loans from officers	0	0	23,603
Repayment of loans from officers	0	0	-23,603
Repayment of notes payable	-50,000	0	-50,000
Proceeds from related-party settlement agreement	0	0	25,000
Proceeds from stock issued for cash	134,640	100,500	235,140
Proceeds from convertible debt	50,000	0	50,000
Proceeds from convertible debt - related party	396,608	100,000	759,276
Net Cash Provided by Financing Activities	531,248	200,500	1,019,416
NET CHANGE IN CASH	7,431	8,131	25,876
CASH AT BEGINNING OF PERIOD	18,445	25,014	0
CASH AT END OF PERIOD	$25,876	$33,145	$25,876

NATURE_OF_OPERATIONS_OF_THE_CO

NATURE OF OPERATIONS OF THE COMPANY	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	NOTE 1 – NATURE OF OPERATIONS OF THE COMPANY
	Innovus Pharmaceuticals, Inc., together with its subsidiaries (collectively referred to as “Innovus” or the “Company”) is an emerging pharmaceuticals company that delivers innovative and uniquely presented and packaged health solutions through its over-the-counter medicines and consumer and health products.  Innovus is located in La Jolla, California.  In its current state, the Company considers itself in a development stage but progressing into the commercial stage based on the expected launch of two of its products for sexual dysfunction and arthritis pain relief in the US and other territories.

LIQUIDITY_AND_PLAN_OF_OPERATIO

LIQUIDITY AND PLAN OF OPERATION	9 Months Ended
	Sep. 30, 2013
Liquidity and Plan Of Operation [Abstract]	'
LiquidityAndPlanOfOperation [Text Block]	'
	NOTE 2 – LIQUIDITY AND PLAN OF OPERATION
	The Company’s operations have been financed primarily through advances from officers and directors and related parties, and to a lesser extent from outside capital.
	On September 9, 2013, the Company entered into a license and distribution agreement with Ovation Pharma SARL (“Ovation”) under which it granted to Ovation an exclusive license to market and sell the Company’s topical treatment for reduced penile sensitivity, CIRCUMserum™, in Morocco.  Ovation may pay the Company up to approximately $11.25 million upon achievement of commercial milestones.  In addition, Ovation has agreed to certain upfront minimum purchases of CIRCUMserum™ based upon an agreed upon transfer price and yearly minimum purchases.  The Company expects its first pre-paid orders to arrive in the fourth quarter of 2013 and to begin shipping products related to this agreement in the first quarter of 2014 (see Note 7).
	On September 9, 2013, the Company entered into a second license and distribution agreement with Ovation under which it granted to Ovation an exclusive license to market and sell the Company’s topical premature ejaculation treatment, EjectDelay™, in Morocco.  Ovation may pay the Company up to approximately $18.6 million – allocated among a fixed upfront license fee and the achievement of regulatory and commercial milestones.  In addition, Ovation has agreed to certain upfront minimum purchases of EjectDelay™ based upon an agreed upon transfer price and minimum yearly purchases. The Company expects products to begin shipping related to this agreement in the fourth quarter of 2013.  For the quarter ended September 30, 2013, the Company recorded $75,000 in deferred revenue, related to the upfront fee, and is entitled to a second regulatory payment in 2014. The Company expects to ship products as soon as the product is registered in Morocco (see Note 7).
	During the nine months ended September 30, 2013, the Company issued $120,000 of convertible debt, of which $50,000 (plus accrued interest) has been converted into 83,103 shares of the Company’s common stock.  The Company also entered into a convertible debenture line of credit agreement with the Company’s President and Chief Executive Officer under which the Company may borrow up to $1,000,000, and sold 416,841 shares of common stock for proceeds of $134,640 to its President and Chief Executive Officer and spouse (see Notes 4, 6 and 8).  Additionally, certain debenture holders extended the maturity of their debentures (see Notes 6 and 11).
	The Company expects that its existing capital resources, including the funds it may borrow under the line of credit convertible debenture entered into with its President and Chief Executive Officer (see Note 6), of which $673,392 remains available to borrow at September 30, 2013, will be sufficient to allow the Company to continue its operations, commence the product development process, and launch selected products through October 1, 2014.  However, the Company’s actual needs will depend on numerous factors, including timing of introducing its products to the marketplace, its ability to attract ex-US distributors for its products, its ability to in-license or develop new product candidates and its ability to finalize merger and acquisition activities.  The Company’s actual capital needs may exceed its anticipated capital needs and the Company may have to substantially modify or terminate current and planned commercial and development operations, enter into strategic relationships, merge or be acquired by another company.  As a result, the Company’s business may be materially harmed, its stock price may be adversely affected, and its ability to raise additional capital may be impaired.
	The Company will need to raise substantial additional funds to support its long-term product development and commercialization programs.  The Company regularly considers various fundraising and strategic alternatives, including, for example, debt or equity financing and merger and acquisition alternatives.  The Company may also seek additional funding through strategic alliances, collaborations, or license agreements and other financing mechanisms.  There can be no assurance that additional financing will be available on acceptable terms, if at all.  If adequate funds are not available, the Company may be required to delay, reduce the scope of, or eliminate one or more of its products; obtain funds through arrangements with licensees or others that may require the Company to relinquish rights to certain of its products that it might otherwise seek to develop or commercialize on its own; significantly restructure operations and implement cost saving initiatives, including but not limited to, reductions in salaries and/or elimination of employees and consultants or cessation of operations; or, merge or be acquired by another company.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	(a) Basis of Presentation and Principles of Consolidation
	These unaudited condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), and include all assets, liabilities, revenues and expenses of the Company and its wholly owned subsidiary: FasTrack Pharmaceuticals, Inc.  All material intercompany transactions and balances have been eliminated.  These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.  Certain information required by U.S. GAAP has been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).  The results for the period ended September 30, 2013, are not necessarily indicative of the results to be expected for the entire fiscal year ended December 31, 2013 or for any future period.  The accompanying financial statements have been prepared in conformity with U.S. GAAP.  Certain items have been reclassified to conform to the current presentation.
	(b) Use of Estimates
	The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods.  Such management estimates include equity-based instruments, income taxes, realizability of deferred tax assets, and intangible assets.  The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances.  Actual results could differ from these estimates under different assumptions or conditions.
	(c) Fair Value Measurement
	The Company’s financial instruments are cash, trade accounts receivable, accounts payable, accrued liabilities, convertible debentures and a convertible debt instrument.  The recorded values of cash, trade accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature.  The recorded values of convertible debentures and convertible debt, net of the discount, approximate the fair value as the interest rate (stated or effective) approximates market rates.
	The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.  The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3).  The three levels of the fair value hierarchy are as follows:
		·	Level 1 measurements are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
		·	Level 2 measurements are inputs other than quoted prices included in Level 1 that are observable either directly or indirectly.
		·	Level 3 measurements are unobservable inputs.
	(d) Concentration of Credit Risk
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and trade accounts receivable.  Cash held with financial institutions may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation (“FDIC”) on such deposits.  As of September 30, 2013 and December 31, 2012, the Company has $75,166 and zero, respectively, in trade accounts receivable.  The Company performs ongoing credit evaluations of its customers and generally does not require collateral.  There have been no write-offs of trade accounts receivable during the periods presented.
	(e) Concentration of Suppliers
	The Company has manufacturing relationships with a number of vendors or manufacturers for its products including: CIRCUMserumTM, EjectDelayTM and the ApeazTM line of products.  Pursuant to these relationships, the Company purchases product through purchase orders with its manufacturers. The Company is in the process of entering into more formal agreements with certain of these manufacturers.
	(f) Income Taxes
	Income taxes are provided for using the asset and liability method whereby deferred tax assets and liabilities are recognized using current tax rates on the difference between the financial statement carrying amounts and the respective tax basis of the assets and liabilities.  The Company provides a valuation allowance on deferred tax assets when it is more likely than not that such assets will not be realized.
	The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit.  For tax positions meeting this standard, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.  The Company recognized interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying statements of operation.  Accrued interest and penalties are included within the related tax liability in the consolidated balance sheets.
	(g) Revenue Recognition, Trade Receivables and Deferred Revenue
	The Company generates revenues from product sales and the licensing of the rights to market and commercialize its products.
	The Company recognizes revenue in accordance with ASC 605, Revenue Recognition.  Revenue is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) price to the buyer is fixed or determinable; and (4) collectability is reasonably assured.
	Product Sales.  The Company ships product to its customers pursuant to purchase agreements or orders.  Revenue from product sales is recognized when substantially all the risks and rewards of ownership have transferred to its customers, the selling price is fixed and collection is reasonably assured.  Product sales under its license agreements are “EX Works”.  The Company has recognized net revenue from product sales that have occurred through Centric Research Institute, Inc.’s (“CRI”) website.  Net revenue is recognized net of cost of the product, warehousing, shipping and royalty costs.  Certain product sales have been recorded as deferred revenue where the product is currently not available.
	License Arrangements.  Payments received by the Company under license arrangements to market and commercialize its products may include non-refundable upfront fees, license fees, milestone payments for specific achievements designated in the agreements, and royalties on sales of products.  The Company considers a variety of factors in determining the appropriate method of accounting under its license arrangements, including whether the various elements can be separated and accounted for individually as separate units of accounting.
	(h) Return Policy
	The Company provides a customer satisfaction warranty on all of its products to customers for a specified amount of time after product delivery.  Estimated return costs are based on historical experience and estimated and recorded when the related sales are recognized.  Any additional costs are recorded when incurred or when they can reasonably be estimated.
	The estimated return reserve, which is included in accounts payable and accrued liabilities, was insignificant at September 30, 2013 and December 31, 2012.
	(i) Research and Development Costs
	Research and development (“R&D”) costs, including research performed under contract by third parties, are expensed as incurred.  Major components of R&D expenses consist of testing, clinical trials, material purchases and regulatory affairs.
	(j) Stock-based Compensation
	The Company accounts for stock-based compensation by recognizing the fair value of stock compensation as an expense in the calculation of net income (loss).  The Company recognizes stock compensation expense in the period in which the employee is required to provide service, which is generally over the vesting period of the individual equity instruments.  Stock and stock options issued in lieu of cash to non-employees for services performed are recorded at the fair value of the stock, stock units or stock options at the time they are issued and are expensed as service is provided.
	(k) Comprehensive Loss
	Comprehensive income (loss) consists of net income (loss) and other gains and losses affecting stockholders’ equity (deficit) that, under U.S. GAAP, are excluded from net income (loss).  Comprehensive income (loss) was the same as net income (loss) for the three and nine months ended September 30, 2013 and 2012 as the Company has no other comprehensive income.
	(l) Earnings per Share
	Basic earnings per share are computed by dividing net loss by the weighted average number of common shares outstanding during the period presented.  Diluted earnings per share are computed using the weighted average number of common shares outstanding during the periods plus the effect of dilutive securities outstanding during the periods.  For the three and nine months ended September 30, 2013 and 2012, basic earnings per share are the same as diluted earnings per share as a result of the Company’s common stock equivalents being anti-dilutive.
	The following reconciliation shows the anti-dilutive shares excluded from the calculation of basic and diluted loss per common share attributable to the Company for the three and nine months ended September 30, 2013 and 2012:
			As of September 30
			2013		2012
	Gross number of shares excluded:
	Stock units			6,300,000		-
	Stock options			40,500		-
	Total			6,340,500		-
	The Company’s convertible debentures provide for automatic conversion of outstanding principal and accrued interest into securities of the Company. Such shares are considered contingently issuable (see Notes 6 and 11).

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 4 – RELATED PARTY TRANSACTIONS
	On June 12, 2013, the Company entered into a subscription agreement for the sale of 416,841 shares of common stock at a purchase price of $0.3230 per share, which is the average closing price of the common stock over the 10-day trading period that ended on the day immediately prior to the date the Company entered into the subscription agreement.  The Company received gross proceeds of approximately $134,640.  The shares were issued to the Company’s President and Chief Executive Officer and his spouse (see Note 8).
	The Company has several convertible debentures outstanding to related parties (see Note 6).

CURRENT_LIABILITIES

CURRENT LIABILITIES	9 Months Ended
	Sep. 30, 2013
Liabilities, Current [Abstract]	'
Current Liabilities Disclosure [Text Block]	'
	NOTE 5 – CURRENT LIABILITIES
	Accrued Compensation
	Accrued compensation includes accruals for employee wages and vacation pay.  The components of accrued compensation, inclusive of payroll taxes, are as follows:
		September 30, 2013		December 31, 2012
	Wages		259,839		-
	Vacation		21,743		-
	Total accrued compensation		281,582		-
	Accrued employee wages relate primarily to wages owed to the Company’s Chief Executive Officer and President.  Under the terms of his employment agreement, wages are to be accrued but no payment made for so long as payment of such salary would jeopardize the Company’s ability to continue as a going concern. There was no accrued compensation for the period ended December 31, 2012.

CONVERTIBLE_DEBENTURES_RELATED

CONVERTIBLE DEBENTURES - RELATED PARTIES	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Related Party Debt Disclosure [Text Block]	'
	NOTE 6 – CONVERTIBLE DEBENTURES – RELATED PARTIES
	January 2012 Convertible Debentures
	In January 2012, the Company issued 8% convertible debentures in the aggregate principal amount of $174,668 (the “January 2012 Debentures”) to six individuals.  Under their original terms, the January 2012 Debentures were payable in cash at the earlier of January 13, 2013 or when the Company completes a financing with minimum gross proceeds of $4 million (the “Financing”), the holders had the right to convert outstanding principal and interest accrued into the Company’s securities that were issued to the investors in the Financing, and, in the event the Company defaulted on repayment, or if the Company failed to complete the Financing by January 13, 2013, the annual interest rate would increase to 13% and the holders would have the option to convert the principal and interest accrued into shares of the Company’s common stock at $0.05 per share.  The Company does not have the right to pre-pay the January 2012 Debentures.  One of the January 2012 Debentures, in the principal amount of $74,668, was issued to one accredited investor in exchange for the liabilities assumed from North Horizon, Inc. upon the 2011 reverse merger.  The five other January 2012 Debentures, in an aggregate principal amount of $100,000, were issued in exchange for new cash infusion by five individuals, three of whom are members of the Company’s Board of Directors.
	The January 2012 Debentures contain an embedded conversion feature which is contingent upon the occurrence of the Financing.  The value of the contingent conversion feature, if beneficial, will be recognized when the contingencies are resolved.
	Through December 31, 2012, $12,000 (plus accrued interest of $435) of the January 2012 Debentures were converted into 16,580 shares of common stock, leaving an aggregate principal balance of $162,668 at December 31, 2012.
	The Financing did not occur by January 13, 2013. However, in January 2013, the five remaining holders of the outstanding January 2012 Debentures agreed to extend the maturity date to January 14, 2014 at the same interest rate of 8% per annum, and to extend the date for optional conversion to common stock to January 14, 2014.  In May and August 2013, four of the five holders of the outstanding January 2012 Debentures agreed to further extend the maturity date to July 1, 2014 at the same interest rate of 8% per annum, and to further extend the date for optional conversion to common stock to July 1, 2014.  On November 11, 2013, four of the five holders of the outstanding January 2012 Debentures agreed to amend and restate the debentures to provide for automatic conversion into securities of the Company upon the earlier of either (a) the closing of the Financing and (b) July 1, 2016 (see Note 11). As of the date of this report as a result of the amendment and restatement of four of the January 2012 Debentures, only one of the January 2012 Debentures (totaling $20,000 in principal) has a maturity date and optional conversion date of January 14, 2014. All such debentures continue to bear interest at a rate of 8% per annum.
	January 2013 Convertible Debenture
	In January 2013, the Company issued a convertible debenture in the principal amount of $70,000 to a director of the Company (the “January 2013 Debenture”).  The terms of the January 2013 Debenture are identical to those of the January 2012 Debentures.
	On November 11, 2013, the holder of the outstanding January 2013 Debenture agreed to amend and restate the debenture to provide for automatic conversion into securities of the Company upon the earlier of either (a) the closing of the Financing and (b) July 1, 2016 (see Note 11). The January 2013 Debenture continues to bear interest at a rate of 8% per annum.
	Line of Credit – Convertible Debenture
	On January 22, 2013, the Company entered into a line of credit convertible debenture with its President and Chief Executive Officer (the “LOC Convertible Debenture”).  Under the terms of its original issuance: (1) the Company could request to borrow up to a maximum principal amount of $250,000 from time to time; (2) amounts borrowed bore an annual interest rate of 8%; (3) the amounts borrowed plus accrued interest is payable in cash at the earlier of January 14, 2014 or when the Company completes a Financing; and (4) the holder had sole discretion to determine whether or not to make an advance upon the Company’s request.
	On March 18, 2013, the LOC Convertible Debenture was amended and restated.  Under its amended and restated terms: (1) the Company could request to borrow up to $500,000; (2) amounts borrowed bore an annual interest rate of 8%; (3) the amounts borrowed plus accrued interest is payable in cash at the earlier of January 14, 2014 or when the Company completes a Financing; (4) the holder committed to advance funds (up to the maximum amount borrowable thereunder) to the Company upon its request if and to the extent the Company will have insufficient liquidity to meet any material payment obligations arising in the ordinary course of business as they come due; and (5) the holder’s funding commitment automatically terminated on the earlier of January 1, 2014 or when the Company completed a financing with minimum net proceeds of at least $500,000.  In addition, the holder’s funding commitment increases by the gross amount of any cash salary, bonus or severance payments provided to the holder under his employment agreement with the Company.  The holder’s salary has been accrued and not paid under the provision of such employment agreement stating that salary payments will be accrued and not paid for so long as payment of such salary would jeopardize the Company’s ability to continue as a going concern.
	On May 6, 2013, the LOC Convertible Debenture was further amended to: (1) extend its maturity date from January 14, 2014 to July 1, 2014 (or, if earlier, when the Company completes a Financing); (2) increase the maximum principal amount borrowable thereunder from $500,000 to $1,000,000; and (3) change the automatic termination of the holder’s funding commitment to the earlier of July 1, 2014 or when the Company completes a financing with minimum net proceeds of at least $1,000,000.  The other material terms of the debenture were not changed.
	During the nine months ended September 30, 2013, the Company borrowed $326,608 under the LOC Convertible Debenture.  As of September 30, 2013, the Company owed a balance of $326,608 in principal amount under the LOC Convertible Debenture, and there was $673,392 remaining available to use.
	On November 11, 2013, the LOC Convertible Debenture was amended and restated (see Note 11).  The LOC Convertible Debenture continues to bear interest at a rate of 8% per annum.
	May 2013 Convertible Debt Instrument
	In May 2013, the Company issued convertible debt in the amount of $50,000, which, together with $1,458 of accrued interest, was converted in September 2013 into 83,103 shares of the Company’s common stock in accordance with the terms of the instrument, thereby fully extinguishing the debt.  During the five months that the debt was outstanding, the Company accreted $8,017 of the debt discount as interest expense.
	Interest Expense
	The Company recognized total interest expense on the January 2012 Debentures, the January 2013 Debenture and the LOC Convertible Debenture including amortization of the discount, of $19,070 and $4,288 for the three months ended September 30, 2013 and 2012, respectively, and $35,128 and $12,308 for the nine months ended September 30, 2013 and 2012, respectively.  At September 30, 2013 and December 31, 2012, there was an aggregate of $559,276 and $162,668, respectively, in principal amount due under the January 2012 Debentures, the January 2013 Debenture and the LOC Convertible Debenture, classified as short and long term liabilities as appropriate. All such debentures continue to bear interest at a rate of 8% per annum.

LICENSE_AGREEMENTS

LICENSE AGREEMENTS	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	NOTE 7 – LICENSE AGREEMENTS
	On April 19, 2013, the Company and CRI entered into an asset purchase agreement (the “CRI Asset Purchase Agreement”) pursuant to which the Company acquired:
		·	all of CRI’s rights in past, present and future CIRCUMserumTM product formulations and presentations, and
		·	an exclusive, perpetual license to commercialize CIRCUMserumTM products in all territories except for the United States.
	CRI will retain commercialization rights for CIRCUMserumTM in the United States.
	In consideration for such assets and license, the Company agreed to issue to CRI shares of the Company’s common stock valued at $250,000 within 10 days of the closing.  The Company issued 631,313 shares to CRI in this regard.  The Company will be required to issue to CRI shares of the Company’s common stock valued at an aggregate of $200,000 for milestones relating to additional clinical data received.  The number of shares to be issued was or will be determined based on the average of the closing price for the 10 trading days immediately preceding the issue date.  CRI will have certain “piggyback” registration rights with respect to the shares described above, which rights provide that, if the Company registers shares of its common stock under the Securities Act in connection with a public offering, CRI will have the right to include such shares in that registration, subject to certain exceptions.  The Company recorded an asset totaling $250,000 related to the CRI Asset Purchase Agreement and will amortize this amount over its estimated useful life of 10 years.  The Company will begin to record amortization of this asset in the fourth quarter of 2013 when it will commence use.  The Company has recorded net sales of CIRCUMserumTM of $445 which relate to Ex US sales from CRI’s website.
	The CRI Asset Purchase Agreement also requires the Company to pay to CRI up to $7 million in cash milestone payments based on first achievement of annual net sales targets plus a royalty based on annual net sales.  The obligation for these payments expires on April 19, 2023 or the expiration of the last of CRI’s patent claims covering the product or its use outside the United States, whichever is sooner.  No sales milestones have been met under this agreement, and royalties owed to CRI were immaterial and included in net revenues.
	In connection with this transaction, the Company engaged a consultant to assist in the technology transfer and manufacturing of the product.  In consideration of such services, the Company agreed to issue to the consultant shares of its common stock valued at an aggregate of $75,000 at various dates following the closing of the CRI transaction.  In each case, the number of shares issuable is determined based on the average of the closing price of the Company’s common stock for the 10 trading days immediately preceding the issue date (see Note 8).
	On September 9, 2013, the Company entered into a license and distribution agreement with Ovation Pharma SARL (“Ovation”) under which it granted to Ovation an exclusive license to market and sell the Company’s topical treatment for reduced penile sensitivity, CIRCUMserum™, in Morocco. Ovation may pay the Company up to approximately $11.25 million upon achievement of commercial milestones. In addition, Ovation has agreed to certain upfront minimum purchases of CIRCUMserum™ based upon an agreed upon transfer price and yearly minimum purchases.
	On September 9, 2013 the Company entered into a second license and distribution agreement with Ovation under which it granted to Ovation an exclusive license to market and sell the Company’s topical premature ejaculation treatment, EjectDelay™, in Morocco. Ovation may pay the Company up to approximately $18.6 million – allocated among a fixed upfront license fee and the achievement of regulatory and commercial milestones.  In addition, Ovation has agreed to certain upfront minimum purchases of EjectDelayTM based upon an agreed upon transfer price and minimum yearly purchases.
	The Company determined that the fixed upfront license fee payment was a separate deliverable under the EjectDelayTM license and distribution agreement. There were no additional obligations or deliverables associated with the license.  However, as of September 30, 2013, as Ovation had not yet received necessary government authorization to make the payment, the Company recorded the upfront license fee as deferred revenue, and will recognize when received.

SHAREHOLDERS_EQUITY

SHAREHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	NOTE 8 – SHAREHOLDERS’ EQUITY
	Capital Stock
	The Company is authorized to issue 150.0 million shares, all of which are common stock with a par value of $.001 per share.
	Issuances of Common Stock
	On January 17, 2013, the Company entered into an investor relations agreement with a third party pursuant to which the Company agreed to issue over the term of the agreement an aggregate of 250,000 shares of common stock in exchange for investor relations’ services to be rendered.  On September 18, 2013, the Company extended the term of the investor relations agreement, and agreed to issue an additional aggregate of 300,000 shares of common stock in exchange for investor relations’ services to be rendered over the term of the agreement.
	As of September 30, 2013, the Company has issued the 250,000 shares according to the original agreement, and an additional 50,000 shares related to the extension.  All issued shares have been valued at the closing price of the Company’s common stock on the date of issuance. The Company recognized expense of $26,000 and $159,450, respectively, under the investor relations agreement during the three and nine months ended September 30, 2013.
	On April 19, 2013, the Company issued 631,313 shares of common stock to CRI pursuant to the CRI Asset Purchase Agreement, which had a fair value of $250,000 (see Note 7).
	In connection with this transaction, the Company engaged a consultant to assist in the technology transfer and manufacturing of the product. In consideration of such services, the Company agreed to issue to the consultant shares of its common stock valued at $75,000 at various dates following the closing of the CRI transaction. For the three and nine months ended September 30, 2013, the Company has issued 66,137 shares and 227,302 shares, respectively. The value of the shares issued for the three and nine months ended September 30, 2013 was $25,000 and $75,000, respectively.
	On June 21, 2013, the Company issued an aggregate of 416,841 shares of common stock for proceeds of $134,640 to a related party (see Note 4).
	On June 28, 2013, the Company entered into an agreement with a consultant to provide drug development pre-clinical consulting services for CIRCUMserumTM and EjectDelayTM.  In consideration of such services, the Company agreed to issue the consultant shares of its common stock valued at $80,200.  The number of shares to be issued will be determined based on the average of the closing price of the Company’s common stock for the 10 trading days immediately preceding the issue date.
	On August 29, 2013, the parties entered into an addendum to this consulting agreement.  In consideration of additional services, the Company agreed to issue the consultant shares of its common stock valued at an additional $23,000.   The number of shares to be issued will be determined based on the average of the closing price of the Company’s common stock for the 10 trading days immediately preceding the issue date.
	As of September 30, 2013, the Company has issued 204,086 shares according to the consulting agreement.  All issued shares have been valued at the closing price of the Company’s common stock on the date of issuance.  The aggregate value of the shares issued was $66,342, which corresponds to the service period of the consultant’s services.
	On May 15, 2013, the Company issued a convertible debt instrument in the amount of $50,000, which, together with $1,458 of accrued interest, was converted on September 25, 2013 into 83,103 shares of the Company’s common stock in accordance with the terms of the instrument, thereby fully extinguishing the debt.  During the five months that the debt was outstanding, the Company accreted $8,017 of the debt discount as interest expense.
	In addition, the Company issued 94,974 and 256,139 shares of common stock to other consultants under consulting agreements for the three and nine months ended September 30, 2013, respectively.  The shares were issued under the Company’s 2013 Equity Incentive Plan.  The aggregate value of the shares issued was $47,332, and $97,333 for the three and nine months ended September 30, 2013, which corresponds to the service period of the respective consultant’s services.
	Equity Plan
	The Company has issued share-based stock, stock unit and option awards to employees, non-executive directors and outside consultants under the Company’s 2013 Equity Incentive Plan (the “Incentive Plan”).  The Incentive Plan allows for the issuance of stock awards, stock unit awards, stock appreciation rights, performance shares and other share-based awards, in addition to stock options.  The exercise price for all equity awards issued under the Incentive Plan is based on the fair market value of the common stock.  Currently, because the Company’s common stock is quoted on the OTC Bulletin Board, the fair market value of the common stock is equal to the last-sale price reported by the OTC Bulletin Board as of the date of determination, or if there were no sales on such date, on the last date preceding such date on which a sale was reported.  Generally, each vested stock unit entitles the recipient to receive one share of Company common stock which is eligible for settlement at the earliest of their termination, a change in control of the Company or a specified date.  Stock units can vest according to a schedule or immediately upon award.  Stock options generally vest over a three-year period, first year cliff vesting with quarterly vesting thereafter on the three-year awards, and have a ten-year life.  Stock options outstanding are subject to time-based vesting as described above and thus are not performance-based.
	As of September 30, 2013, there were 6,300,000 stock units and 40,500 shares subject to options outstanding, the Company issued 460,225 shares as payments for services, and 3,199,551 shares were available for future grants under the Incentive Plan.
	Stock-based Compensation
	The Company accounts for stock based compensation in accordance with ASC 718, Stock Based Compensation, which requires the recognition of the fair value of stock compensation as an expense in the calculation of net income.  ASC 718 requires that stock-based compensation expense be based on awards that are ultimately expected to vest.  Stock-based compensation for the three and nine months ended September 30, 2013 and 2012 have been reduced for estimated forfeitures.  When estimating forfeitures, voluntary termination behaviors, as well as trends of actual option forfeitures, are considered.  To the extent actual forfeitures differ from the Company’s current estimates, cumulative adjustments to stock-based compensation expense are recorded.
	Except for transactions with employees and directors that are within the scope of ASC 718, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.
	The stock-based compensation expense for the three and nine months ended September 30, 2013 was $289,270 and $1,962,379, respectively.  The Company calculates the fair value of each equity award on the date of grant using the Black-Scholes option-pricing model.  The Company did not grant any equity awards during the nine months ended September 30, 2012.  For the three and nine months ended September 30, 2013 the following weighted average assumptions were utilized for the stock option granted during the period:
		September 30, 2013
	Expected life (in years)	6
	Expected volatility	235.7%-243.15%
	Average risk free interest rate	1.71%-1.75%
	Dividend yield	0%
	The dividend yield of zero is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends.  Expected volatility is based on the historical volatility of the Company’s common shares over the period commensurate with the expected life of the options.  Expected life in years is based on the “simplified” method as permitted by ASC Topic 718.  The Company believes that all stock options issued under its stock option plans meet the criteria of “plain vanilla” stock options.  The Company uses a term of 6 years for all employee stock options.  The risk free interest rate is based on average rates for 5 and 7 year treasury notes as published by the Federal Reserve.
	The following table summarizes the number of options outstanding and the weighted average exercise price:
						Weighted
				Weighted		remaining
				average exercise		contractual life		Aggregate
		Options		price		(years)		intrinsic value
	Outstanding at December 31 ,2012		-	$	-		-	$	-
	Granted		40,500		0.49		9.8		16,800
	Exercised		-		-		-		-
	Cancelled		-		-		-		-
	Forfeited		-		-		-		-
	Outstanding at September 30, 2013		40,500	$	0.49		9.8	$	16,800
	Vested at September 30, 2013		10,500	$	0.9		10	$	-
	The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding options and the quoted price of the Company’s common shares that were in the money at September 30, 2013.
	The Company granted 10,500 and 40,500 options during the three and nine months ended September 30, 2013, respectively.  The weighted average grant date fair value per share of options granted during the nine months ended September 30, 2013 was $0.48.  No options were granted during the nine months ended September 30, 2012.
	At September 30, 2013 and 2012, the aggregate intrinsic value of all outstanding options was $16,800 and zero, respectively.  No options were exercised under the Incentive Plan during the nine months ended September 30, 2013 or 2012.
	Stock Units
	The following table summarizes the number of stock units outstanding:
		Stock Units
	Outstanding at December 31, 2012	-
	Granted	7,050,000
	Expired	-
	Cancelled	-750,000
	Forfeited	-
	Outstanding at September 30, 2013	6,300,000
	Vested at September 30, 2013	3,058,333
	The vested stock units at September 30, 2013 have not settled and are not showing as issued and outstanding shares of the Company.  Settlement of these vested stock units will occur on the earliest of (i) the date of termination of service of the employee or consultant, (ii) change of control of the Company, or (iii) 10 years from date of issuance.  Settlement of vested stock units may be made in the form of (i) cash, (ii) shares, or (iii) any combination of both, as determined by the committee.
	On February 15, 2013, the Company entered into a stock unit agreement with its President and Chief Executive Officer pursuant to his employment agreement.  Under the terms of the agreement, the Company issued 6,000,000 stock units, 2,000,000 of the units vested immediately, while the remaining 4,000,000 vest in eight equal quarterly installments until January 1, 2015, subject to his continued service to the Company as of the vesting date.
	On February 15, 2013, the Company entered into a stock unit agreement with a consultant.  Under the terms of the agreement, the Company issued 300,000 stock units, with one thirty-sixth of the units vesting on the 7th of each month beginning on March 7, 2013, subject to the consultant’s continued service to the Company as of the vesting date.  At September 30, 2013, 58,331 shares have vested under this agreement.
	The Company recognized compensation expense of $317,363 and $1,848,763 for the vested portion of the stock units for the three and nine month periods ended September 30, 2013.

NON_CASH_FINANCING_ACTIVITIES

NON CASH FINANCING ACTIVITIES	9 Months Ended
	Sep. 30, 2013
Non Cash Financing Activities Disclosure [Abstract]	'
Non Cash Financing Activities [Text Block]	'
	NOTE 9 – NON CASH FINANCING ACTIVITIES
	Nine-month period ended September 30, 2013:
		·	The Company issued of 631,313 shares of common stock (valued at $250,000) in connection with the CRI Asset Purchase Agreement, as described in Note 8.
		·	The Company issued 83,103 shares of common stock upon conversion of a convertible note as described in Note 6.
	Nine-month period ended September 30, 2012:
		·	$74,668 payable to a related party was converted into a convertible note, as described in Note 6.
		·	The Company issued 135,888 shares of common stock related to the conversion of the Apricus Bio convertible promissory note that was originally issued in December 2011 and deemed contributed to capital in March 2012.
		·	A convertible debenture in the principal amount of $12,000 plus accrued interest of $435 was converted into 16,580 shares of common stock, as described in Note 6.
		·	Contingent liability in the amount of $28,926 was reclassified to equity due to expiration of the rescission rights, none of which were exercised.

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2013
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	'
	NOTE 10 – RECENT ACCOUNTING PRONOUNCEMENTS
	In December 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2011-11, Disclosures about Offsetting Assets and Liabilities.  The standard requires enhanced disclosures about assets and liabilities that are subject to a master netting agreement or when the right of offset exists.  In January 2013, the FASB issued ASU No. 2013-01, Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities.  This pronouncement limits the scope of ASU No. 2011-1.  The standards’ disclosure requirements are retrospective and were effective beginning in first quarter 2013.  The adoption of ASU 2011-11 had no impact on the Company’s financial position or results of operations.
	In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“AOCI”).  This standard requires reporting, in one place, information about reclassifications out of AOCI by component.  An entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of AOCI by the respective line items of net income, but only if the amount is reclassified in its entirety in the same reporting period.  For amounts that are not required to be reclassified to net income in their entirety, an entity is required to cross-reference to other currently required disclosures that provide additional detail about those amounts.  The information required by this standard must be presented in one place, either parenthetically on the face of the financial statements by income statement line item or in a note.  The adoption of ASU 2013-02 had no impact on the Company’s financial position or results of operations.
	In March 2013, the FASB issued amendments to address the accounting for the cumulative translation adjustment when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity.  The amendments are effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013 (early adoption is permitted).  The adoption of the amendment had no impact on the Company’s financial position or results of operations.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 11 – SUBSEQUENT EVENTS
	Amendment and Restatement of January 2012 and 2013 Convertible Debentures
	On November 11, 2013, the Company and the holders of four of the five outstanding January 2012 Debentures and the holder of the outstanding January 2013 Debenture, agreed to amend and restate the terms of such debentures to provide for automatic conversion of outstanding principal and accrued interest into securities of the Company upon the earlier of either (a) the closing of the Financing and (b) July 1, 2016.  The securities to be issued will be either the Company’s securities that are issued to the investors in the Financing or, if the Financing does not occur by July 1, 2016, shares of the Company’s common stock based on a conversion price of $0.312 per share. These debentures have an aggregate principal amount of $212,668 and are held by various investors, including related parties.  The other terms of these five amended and restated debentures were not changed (see Note 6).   All such debentures continue to bear interest at a rate of 8% per annum.
	Amendment and Restatement of LOC Convertible Debenture
	On November 11, 2013, the Company and the holder of the LOC Convertible Debenture agreed to amend and restate its terms to provide that: (1) the debenture will automatically convert into securities of the Company upon the earlier of either (a) the closing of the Financing and (b) July 1, 2016 and (2) the holder’s funding commitment will automatically terminate on the earlier of either (a) when the Company completes a financing with minimum net proceeds of at least $4,000,000 and (b) July 1, 2016. The securities to be issued upon automatic conversion will be either the Company’s securities that are issued to the investors in the Financing or, if the Financing does not occur by July 1, 2016, shares of the Company’s common stock based on a conversion price of $0.312 per share. The debenture continues to bear interest at a rate of 8% per annum. The other material terms of the debenture were not changed (see Note 6).

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis Of Presentation And Principles Of Consolidation [Policy Text Block]	'
	(a) Basis of Presentation and Principles of Consolidation
	These unaudited condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), and include all assets, liabilities, revenues and expenses of the Company and its wholly owned subsidiary: FasTrack Pharmaceuticals, Inc.  All material intercompany transactions and balances have been eliminated.  These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.  Certain information required by U.S. GAAP has been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).  The results for the period ended September 30, 2013, are not necessarily indicative of the results to be expected for the entire fiscal year ended December 31, 2013 or for any future period.  The accompanying financial statements have been prepared in conformity with U.S. GAAP.  Certain items have been reclassified to conform to the current presentation.
Use of Estimates, Policy [Policy Text Block]	'
	(b) Use of Estimates
	The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods.  Such management estimates include equity-based instruments, income taxes, realizability of deferred tax assets, and intangible assets.  The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances.  Actual results could differ from these estimates under different assumptions or conditions.
Fair Value Measurement, Policy [Policy Text Block]	'
	(c) Fair Value Measurement
	The Company’s financial instruments are cash, trade accounts receivable, accounts payable, accrued liabilities, convertible debentures and a convertible debt instrument.  The recorded values of cash, trade accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature.  The recorded values of convertible debentures and convertible debt, net of the discount, approximate the fair value as the interest rate (stated or effective) approximates market rates.
	The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.  The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3).  The three levels of the fair value hierarchy are as follows:
		·	Level 1 measurements are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
		·	Level 2 measurements are inputs other than quoted prices included in Level 1 that are observable either directly or indirectly.
		·	Level 3 measurements are unobservable inputs.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	(d) Concentration of Credit Risk
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and trade accounts receivable.  Cash held with financial institutions may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation (“FDIC”) on such deposits.  As of September 30, 2013 and December 31, 2012, the Company has $75,166 and zero, respectively, in trade accounts receivable.  The Company performs ongoing credit evaluations of its customers and generally does not require collateral.  There have been no write-offs of trade accounts receivable during the periods presented.
Concentration Of Suppliers, Policy [Policy Text Block]	'
	(e) Concentration of Suppliers
	The Company has manufacturing relationships with a number of vendors or manufacturers for its products including: CIRCUMserumTM, EjectDelayTM and the ApeazTM line of products.  Pursuant to these relationships, the Company purchases product through purchase orders with its manufacturers. The Company is in the process of entering into more formal agreements with certain of these manufacturers.
Income Tax, Policy [Policy Text Block]	'
	(f) Income Taxes
	Income taxes are provided for using the asset and liability method whereby deferred tax assets and liabilities are recognized using current tax rates on the difference between the financial statement carrying amounts and the respective tax basis of the assets and liabilities.  The Company provides a valuation allowance on deferred tax assets when it is more likely than not that such assets will not be realized.
	The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit.  For tax positions meeting this standard, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.  The Company recognized interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying statements of operation.  Accrued interest and penalties are included within the related tax liability in the consolidated balance sheets.
Revenue Recognition, Trade Receivables And Deferred Revenue, Policy [Policy Text Block]	'
	(g) Revenue Recognition, Trade Receivables and Deferred Revenue
	The Company generates revenues from product sales and the licensing of the rights to market and commercialize its products.
	The Company recognizes revenue in accordance with ASC 605, Revenue Recognition.  Revenue is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) price to the buyer is fixed or determinable; and (4) collectability is reasonably assured.
	Product Sales.  The Company ships product to its customers pursuant to purchase agreements or orders.  Revenue from product sales is recognized when substantially all the risks and rewards of ownership have transferred to its customers, the selling price is fixed and collection is reasonably assured.  Product sales under its license agreements are “EX Works”.  The Company has recognized net revenue from product sales that have occurred through Centric Research Institute, Inc.’s (“CRI”) website.  Net revenue is recognized net of cost of the product, warehousing, shipping and royalty costs.  Certain product sales have been recorded as deferred revenue where the product is currently not available.
	License Arrangements.  Payments received by the Company under license arrangements to market and commercialize its products may include non-refundable upfront fees, license fees, milestone payments for specific achievements designated in the agreements, and royalties on sales of products.  The Company considers a variety of factors in determining the appropriate method of accounting under its license arrangements, including whether the various elements can be separated and accounted for individually as separate units of accounting.
Return, Policy [Policy Text Block]	'
	(h) Return Policy
	The Company provides a customer satisfaction warranty on all of its products to customers for a specified amount of time after product delivery.  Estimated return costs are based on historical experience and estimated and recorded when the related sales are recognized.  Any additional costs are recorded when incurred or when they can reasonably be estimated.
	The estimated return reserve, which is included in accounts payable and accrued liabilities, was insignificant at September 30, 2013 and December 31, 2012.
Research and Development Expense, Policy [Policy Text Block]	'
	(i) Research and Development Costs
	Research and development (“R&D”) costs, including research performed under contract by third parties, are expensed as incurred.  Major components of R&D expenses consist of testing, clinical trials, material purchases and regulatory affairs.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	(j) Stock-based Compensation
	The Company accounts for stock-based compensation by recognizing the fair value of stock compensation as an expense in the calculation of net income (loss).  The Company recognizes stock compensation expense in the period in which the employee is required to provide service, which is generally over the vesting period of the individual equity instruments.  Stock and stock options issued in lieu of cash to non-employees for services performed are recorded at the fair value of the stock, stock units or stock options at the time they are issued and are expensed as service is provided.
Comprehensive Loss, Policy [Policy Text Block]	'
	(k) Comprehensive Loss
	Comprehensive income (loss) consists of net income (loss) and other gains and losses affecting stockholders’ equity (deficit) that, under U.S. GAAP, are excluded from net income (loss).  Comprehensive income (loss) was the same as net income (loss) for the three and nine months ended September 30, 2013 and 2012 as the Company has no other comprehensive income.
Earnings Per Share, Policy [Policy Text Block]	'
	(l) Earnings per Share
	Basic earnings per share are computed by dividing net loss by the weighted average number of common shares outstanding during the period presented.  Diluted earnings per share are computed using the weighted average number of common shares outstanding during the periods plus the effect of dilutive securities outstanding during the periods.  For the three and nine months ended September 30, 2013 and 2012, basic earnings per share are the same as diluted earnings per share as a result of the Company’s common stock equivalents being anti-dilutive.
	The following reconciliation shows the anti-dilutive shares excluded from the calculation of basic and diluted loss per common share attributable to the Company for the three and nine months ended September 30, 2013 and 2012:
			As of September 30
			2013		2012
	Gross number of shares excluded:
	Stock units			6,300,000		-
	Stock options			40,500		-
	Total			6,340,500		-
	The Company’s convertible debentures provide for automatic conversion of outstanding principal and accrued interest into securities of the Company. Such shares are considered contingently issuable (see Notes 6 and 11).

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following reconciliation shows the anti-dilutive shares excluded from the calculation of basic and diluted loss per common share attributable to the Company for the three and nine months ended September 30, 2013 and 2012:
		As of September 30
		2013		2012
	Gross number of shares excluded:
	Stock units		6,300,000		-
	Stock options		40,500		-
	Total		6,340,500		-

CURRENT_LIABILITIES_Tables

CURRENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2013
Liabilities, Current [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued compensation includes accruals for employee wages and vacation pay.  The components of accrued compensation, inclusive of payroll taxes, are as follows:
		September 30, 2013		December 31, 2012
	Wages		259,839		-
	Vacation		21,743		-
	Total accrued compensation		281,582		-

SHAREHOLDERS_EQUITY_Tables

SHAREHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	'
	For the three and nine months ended September 30, 2013 the following weighted average assumptions were utilized for the stock option granted during the period:
		September 30, 2013
	Expected life (in years)	6
	Expected volatility	235.7%-243.15%
	Average risk free interest rate	1.71%-1.75%
	Dividend yield	0%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes the number of options outstanding and the weighted average exercise price:
						Weighted
				Weighted		remaining
				average exercise		contractual life		Aggregate
		Options		price		(years)		intrinsic value
	Outstanding at December 31 ,2012		-	$	-		-	$	-
	Granted		40,500		0.49		9.8		16,800
	Exercised		-		-		-		-
	Cancelled		-		-		-		-
	Forfeited		-		-		-		-
	Outstanding at September 30, 2013		40,500	$	0.49		9.8	$	16,800
	Vested at September 30, 2013		10,500	$	0.9		10	$	-
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	'
	The following table summarizes the number of stock units outstanding:
		Stock Units
	Outstanding at December 31, 2012	-
	Granted	7,050,000
	Expired	-
	Cancelled	-750,000
	Forfeited	-
	Outstanding at September 30, 2013	6,300,000
	Vested at September 30, 2013	3,058,333

LIQUIDITY_AND_PLAN_OF_OPERATIO1

LIQUIDITY AND PLAN OF OPERATION (Details Textual) (USD $)

9 Months Ended

12 Months Ended

59 Months Ended

9 Months Ended

1 Months Ended

6 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 11, 2013

Sep. 09, 2013

Jun. 21, 2013

Jun. 30, 2013

Sep. 30, 2013

Jan. 22, 2013

Sep. 30, 2013

License Agreement Terms [Member]

License Agreement Terms [Member]

License Agreement Terms [Member]

President and Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

Board [Member]

Convertible Debentures - Related Party

'

'

'

'

'

'

'

'

'

'

'

$120,000

Line of Credit Facility, Maximum Borrowing Capacity

673,392

'

'

673,392

'

'

'

'

'

1,000,000

250,000

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

416,841

416,841

416,841

'

'

Proceeds From Issuance Of Common Stock

134,640

100,500

'

235,140

'

'

'

'

'

134,640

'

'

Deferred Revenue, Revenue Recognized

75,136

0

'

75,136

75,000

'

'

'

'

0

'

'

Debt Instrument, Face Amount

50,000

'

'

50,000

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued

83,103

16,580

16,580

'

'

'

'

'

'

'

'

'

Maximum Milestone Payments

'

'

'

'

'

$18,600,000

$11,250,000

'

'

'

'

'

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,340,500	0
Stock options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	40,500	0
Stock units [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,300,000	0

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accounts Receivable, Net, Current, Total	$75,165	$0

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)	6 Months Ended	9 Months Ended		59 Months Ended	1 Months Ended	6 Months Ended	9 Months Ended
	Jun. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Jun. 21, 2013	Jun. 30, 2013	Sep. 30, 2013
					President and Chief Executive Officer [Member]	President and Chief Executive Officer [Member]	President and Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues	'	'	'	'	416,841	416,841	416,841
Stock Issued During Period Shares Price Per Share	$0.32	'	'	'	'	'	'
Proceeds From Issuance Of Common Stock	'	$134,640	$100,500	$235,140	'	'	$134,640

CURRENT_LIABILITIES_Details

CURRENT LIABILITIES (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Wages	$259,839	$0
Vacation	21,743	0
Total accrued compensation	$281,582	$0

CONVERTIBLE_DEBENTURES_RELATED1

CONVERTIBLE DEBENTURES - RELATED PARTIES (Details Textual) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

9 Months Ended

1 Months Ended

Jan. 31, 2013

Jan. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Jan. 13, 2013

Nov. 30, 2013

Jan. 31, 2013

6-May-13

Mar. 18, 2013

Jan. 22, 2013

Sep. 30, 2013

Sep. 30, 2013

Jan. 13, 2012

Jan. 13, 2013

Jan. 31, 2013

Jan. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 25, 2013

Dec. 31, 2012

Subsequent Event [Member]

Director [Member]

President and Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

One Holder [Member]

One Holder [Member]

Five Holder [Member]

January 2012 Debenture [Member]

January 2012 Debenture [Member]

January 2013 Debenture [Member]

January 2013 Debenture [Member]

Accured Interest [Member]

Accured Interest [Member]

Subsequent Event [Member]

Convertible Promissory Notes Approved For Issuance

'

$174,668

'

'

'

'

'

'

'

'

'

'

'

'

'

$74,668

'

'

'

'

'

'

'

Minimum Proceeds From Debt To Convert Securities

'

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate Increase

'

'

'

'

'

'

'

13.00%

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

Debt Conversion Convertible Instrument Share Price

$0.05

'

'

'

'

'

'

'

$0.31

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Amount

'

'

'

'

50,000

12,000

12,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument Interest Accrued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,458

435

Debt Conversion, Converted Instrument, Shares Issued (in shares)

'

'

'

'

83,103

16,580

16,580

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Expense, Related Party

'

'

19,070

4,288

35,128

12,308

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Debt

'

'

50,000

'

50,000

'

'

'

'

70,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum

'

'

'

'

'

'

'

'

'

'

'

8.00%

8.00%

'

'

'

'

8.00%

8.00%

'

'

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14-Jan-14

'

'

14-Jan-14

'

'

'

'

'

Requirement Of Additional Funds For Insufficient Liquidity Maximum Limit

'

'

'

'

'

'

'

'

'

'

1,000,000

500,000

4,000,000

'

'

'

'

'

'

'

'

'

'

Fund Raised By Convertible Debentures Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'the holders funding commitment automatically terminated on the earlier of January 1, 2014 or when the Company completed a financing with minimum net proceeds of at least $500,000.

'

'

'

'

'

'

'

'

'

Long-term Line of Credit

'

'

326,608

'

326,608

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Debenture Approved For Issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

Requirement Of Additional Funds For Insufficient Liquidity, Description

'

'

'

'

'

'

'

'

'

'

'increase the maximum principal amount borrowable thereunder from $500,000 to $1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Debt Related Party

'

'

559,276

'

559,276

'

162,668

'

'

'

'

'

'

'

20,000

'

'

'

'

'

'

'

'

Interest and Debt Expense, Total

'

'

'

'

8,017

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line Of Credit Facility, Maximum Borrowing Capacity

'

'

$673,392

'

$673,392

'

'

'

'

'

'

'

$250,000

$1,000,000

'

'

'

'

'

$673,392

'

'

'

LICENSE_AGREEMENTS_Details_Tex

LICENSE AGREEMENTS (Details Textual) (USD $)	9 Months Ended					9 Months Ended		1 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 11, 2013	Sep. 09, 2013	Sep. 09, 2013	Sep. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013
		License Agreement Terms [Member]	License Agreement Terms [Member]	License Agreement Terms [Member]	Second License Agreement Terms [Member]	CRI Asset Purchase Agreement [Member]	CRI Asset Purchase Agreement [Member]	Consultant [Member]	Consultant [Member]
							Criteria One [Member]		CRI Asset Purchase Agreement [Member]
Maximum Milestone Payments	'	'	$18,600,000	$11,250,000	$18,600,000	$7,000,000	'	'	'
Stock To Be Issued During Period For Services Value	250,000	'	'	'	'	250,000	200,000	80,200	'
Stock To Be Issued During Period For Services Shares	'	'	'	'	'	631,313	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'	'	'10 years	'	'	'
Sales Revenue Ex US Sales	'	'	'	'	'	445	'	'	'
Common Stock Issued	'	'	'	'	'	'	'	'	75,000
Deferred Revenue	'	$75,000	'	'	'	'	'	'	'

SHAREHOLDERS_EQUITY_Details

SHAREHOLDERS' EQUITY (Details)	9 Months Ended
	Sep. 30, 2013
Expected life (in years)	'6 years
Dividend yield	0.00%
Maximum [Member]	'
Expected volatility	243.15%
Average risk free interest rate	1.75%
Minimum [Member]	'
Expected volatility	235.70%
Average risk free interest rate	1.71%

SHAREHOLDERS_EQUITY_Details_1

SHAREHOLDERS' EQUITY (Details 1) (USD $)	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013
		Employee Stock Option [Member]	Employee Stock Option [Member]
Stock Options, Outstanding Beginning Balance	'	'	0
Options, Granted	'	10,500	40,500
Options, Exercised	'	'	0
Options, Cancelled	'	'	0
Options, Forfeited	'	'	0
Stock Options, Outstanding Ending Balance	'	40,500	40,500
Options, Vested	'	'	10,500
Weighted average exercise price, Outstanding Beginning Balance	'	'	$0
Weighted average exercise price, Granted	'	'	$0.49
Weighted average exercise price, Exercised	'	'	$0
Weighted average exercise price, Cancelled	'	'	$0
Weighted average exercise price, Forfeited	'	'	$0
Weighted average exercise price, Outstanding Ending Balance	'	$0.49	$0.49
Weighted average exercise price, Vested	'	$0.90	$0.90
Weighted average remaining contractual life (years), Outstanding	'	'	'9 years 9 months 18 days
Weighted average remaining contractual life (years), Granted	'	'	'9 years 9 months 18 days
Weighted average remaining contractual life (years), Vested	'	'	'10 years
Aggregate intrinsic value, Outstanding	$0	$16,800	$16,800
Aggregate intrinsic value, Granted	'	'	$16,800

SHAREHOLDERS_EQUITY_Details_2

SHAREHOLDERS' EQUITY (Details 2) (Stock Units [Member])	9 Months Ended
	Sep. 30, 2013
Stock Units [Member]	'
Stock Options, Outstanding Beginning Balance	0
Stock Units, Granted	7,050,000
Stock Units, Expired	0
Stock Units,Cancelled	-750,000
Stock Units, Forfeited	0
Stock Options, Outstanding Ending Balance	6,300,000
Stock Units, Vested	3,058,333

SHAREHOLDERS_EQUITY_Details_Te

SHAREHOLDERS' EQUITY (Details Textual) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

59 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

6 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

0 Months Ended

9 Months Ended

59 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Apr. 30, 2013

Jun. 21, 2013

Jun. 30, 2013

Sep. 30, 2013

Feb. 28, 2013

Sep. 30, 2013

Sep. 30, 2013

Aug. 31, 2013

Jan. 17, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Shares Issued [Member]

Consultant [Member]

Consultant [Member]

Consultant [Member]

Consultant [Member]

CRI Asset Purchase Agreement [Member]

President and Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

Stock Units [Member]

Stock Units [Member]

Stock Units [Member]

Consulting Agreement [Member]

Investor Relations Agreement [Member]

Investor Relations Agreement [Member]

Investor Relations Agreement [Member]

Investor Relations Agreement [Member]

Apricus Bio Convertible Promissory Note [Member]

Shares Issued [Member]

Additional Shares Issued [Member]

Share-based Goods and Non-employee Services Transaction, Quantity of Securities Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

300,000

250,000

50,000

'

Common Stock, Shares Authorized

150,000,000

150,000,000

'

150,000,000

150,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par Or Stated Value Per Share

$0.00

$0.00

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issuance Expenses

$26,000

$159,450

'

'

'

'

'

'

'

'

$47,332

'

$97,333

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement by Share Based Payment Award Options Vested In Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

58,331

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

'

'

'

10,500

40,500

'

'

'

'

'

'

'

'

'

6,000,000

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance

'

'

'

'

'

40,500

40,500

0

'

'

'

'

'

'

'

'

'

'

6,300,000

6,300,000

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services

'

'

'

'

'

'

'

'

460,225

'

66,137

227,302

'

631,313

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

416,841

416,841

416,841

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

3,199,551

3,199,551

'

'

3,199,551

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Future

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

317,363

1,848,763

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

'

$0.48

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

134,640

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation, Total

289,270

1,962,379

'

'

1,962,379

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value

'

'

0

'

'

16,800

16,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Issued for Services

'

'

'

'

'

'

'

'

'

'

25,000

'

75,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Debt

50,000

50,000

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Interest On Convertible Debt

1,458

1,458

'

'

1,458

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock To Be Issued During Period For Services Value

'

250,000

'

'

'

'

'

'

'

80,200

'

'

'

'

'

'

'

300,000

'

'

23,000

'

'

'

'

'

Stock Issued During Period Value Issued For Asset Purchase

'

$250,000

'

'

'

'

'

'

'

'

'

'

'

$250,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued

'

83,103

16,580

16,580

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

135,888

NON_CASH_FINANCING_ACTIVITIES_

NON CASH FINANCING ACTIVITIES (Details Textual) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Debt Conversion, Converted Instrument, Shares Issued (in shares)	83,103	16,580	16,580
Debt Conversion, Original Debt, Amount	'	$74,668	'
Debt Conversion, Converted Instrument, Amount	50,000	12,000	12,000
Debt Instrument, Increase, Accrued Interest	'	435	'
Expiration Of Fastrack Rescission Offer Value	'	28,926	'
Stock Issued During Period Shares Issued For Asset Purchase	631,313	'	'
Stock Issued During Period Value Issued For Asset Purchase	$250,000	'	'
Apricus Bio Convertible Promissory Note [Member]	'	'	'
Debt Conversion, Converted Instrument, Shares Issued (in shares)	'	135,888	'

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	1 Months Ended				1 Months Ended
	Jan. 31, 2013	Sep. 30, 2013	Dec. 31, 2012	Nov. 30, 2013	Nov. 30, 2013
				Debenture [Member]	Subsequent Event [Member]
Debt Conversion Convertible Instrument Share Price	$0.05	'	'	'	$0.31
Convertible Debt Related Party	'	$559,276	$162,668	$212,668	'
Debt Conversion Convertible Instrument Amount	'	'	'	'	$4,000,000